Figure 3.
Potential use of lncRNAs in CRC screening, diagnosis, prognosis, and treatment. First, Polymorphisms within lncRNA-encompassing regions may contribute to susceptibility to CRC; second, lncRNAs isolated from blood samples may be substantial biomarkers for early diagnosis and prognosis of CRC; third, the aberrant lncRNA expression in CRC correlates with patient survival or treatment outcome, providing the theoretical rationale for using lncRNAs as promising therapeutic targets.